Vor Biopharma Inc logo

VOR

Vor Biopharma Inc

$5.1

Earnings Summary

Revenue
$0Mn
Net Profits
$-22.74Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Vor Biopharma Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Vor Biopharma Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Vor Biopharma Inc’s net profit fell -65.69% since last year same period to $-22.74Mn in the Q1 2022. On a quarterly growth basis, Vor Biopharma Inc has generated -24.57% fall in its net profits since last 3-months.

Net Profit Margins:

Vor Biopharma Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Vor Biopharma Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Vor Biopharma Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.65
EPS Estimate Current Year
-0.65

Highlights

EPS Estimate Current Quarter:

Vor Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.65 - a -27.45% fall from last quarter’s estimates.

EPS Estimate Current Year:

Vor Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.65.

Key Ratios

Key ratios of the Vor Biopharma Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.61
Return on Assets (ROA)
-0.27
Return on Equity (ROE)
-0.52
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Vor Biopharma Inc’s earning per share (EPS) jumped 8.96% since last year same period to -0.61 in the Q1 2022. This indicates that the Vor Biopharma Inc has generated 8.96% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Vor Biopharma Inc’s return on assets (ROA) stands at -0.27.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Vor Biopharma Inc’s return on equity (ROE) stands at -0.52.

Dividend Per Share (DPS):

Vor Biopharma Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.51
-0.61
-19.61%

Company Information

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Organisation
Vor Biopharma Inc
Employees
88